OncBioMune announced that it has cumulatively completed a $110 million Pre-IPO round of financing to accelerate the global development process of CAR-T for solid tumors.
The global leader in innovative oncology immunotherapy, Oricell Therapeutics Holdings Limited (hereinafter referred to as "Oricell", "Oricell Therapeutics", or "the Company") today officially announced the successful completion of a US$110 million Pre-IPO round of financing. This round of financing was jointly led by Vivo Capital, Beijing Medical and Health Industry Investment Fund, Qiming Venture Partners, and a globally leading medical fund. Well-known institutions such as a certain international sovereign fund, Yizhuang State-owned Investment, Luxin Venture Capital, NGS (Australian pension fund), Lichen Investment, and Ruifeng Capital participated in the follow-on investment. The funds raised in this round will be mainly used to accelerate Oricell's international strategic layout, promote the global multi-center clinical development of its core pipeline, further strengthen its technological barriers in the field of cell therapy, and accelerate the value realization of its industrialization pipeline, making full preparations for the upcoming milestones in the capital market.
As a leading enterprise in the field of cell therapy drugs, Oricell has always been committed to developing CAR-T cell therapies with global clinical value and has obtained confirmatory proof-of-concept (POC) clinical data in multiple pipelines. Relying on the company's independently developed Ori®Ab antibody screening and engineering platform, Ori®Armoring structure enhancement platform, and OnGo(Fast) CMC rapid process expertise, Oricell has successfully built a differentiated product pipeline, taking a leading position in the global CAR-T technology competition.
Oricell's core product includes Ori-C101, an autologous CAR-T drug targeting GPC3 for the treatment of advanced hepatocellular carcinoma (HCC). This product has completed investigator-initiated clinical trials (IIT) and Phase I registration clinical trials and is about to launch pivotal clinical trials. The released clinical data have demonstrated excellent efficacy and safety characteristics, and the relevant results have been presented at many top international academic conferences such as ASCO (American Society of Clinical Oncology Annual Meeting). With the current positive clinical progress, Ori-C101 is expected to become the world's first approved CAR-T drug for hepatocellular carcinoma.
In addition to the core pipeline, Oricell's full-platform technology system is continuously incubating multiple next-generation multi-target, multi-mechanism CAR-T products, including secretory, rapid production, and multiple in vivo CAR-T projects.
Dr. Yang Huanfeng, Chairman and CEO of Oricell, said: "We are very grateful to all investors for their high recognition of the company's vision and technological strength. This round of financing is an important milestone in Oricell's development. We will continue to focus on the global clinical advancement of our core pipeline, deepen the research and development of revolutionary technologies such as in vivo CAR-T and solid tumor CAR-T, and make full use of the company's multiple advantages in technological accumulation, policy environment, and market demand to accelerate the development of clinical-stage products, reduce costs, and increase accessibility. Our goal is to bring new hopes of cure to global cancer patients with more breakthrough cell therapy solutions and steadily move towards the ranks of global leading immunotherapy companies."
Mr. Fu Shan, Managing Partner of Vivo Capital, said: "Cell therapy is the cornerstone of future cancer treatment, and solid tumors have always been a fortress to be conquered in this field. Oricell has not only demonstrated globally leading clinical data on the GPC3 target but also made forward-looking and practical arrangements in next-generation technologies such as in vivo CAR-T. Vivo Capital is optimistic about Oricell's 'platform + pipeline' dual-driven model and believes that it has the ability to become a global enterprise defining the next generation of cell therapy standards. We look forward to leveraging Vivo's global ecological resources to help Oricell accelerate its internationalization process."
Mr. Ren Peng, Chairman and General Manager of Beijing Shunxi Private Equity Fund Management Co., Ltd., said: "We believe that cell therapy is an important direction for conquering solid tumors. The clinical progress of Oricell's GPC3 CAR-T in the treatment of liver cancer has greatly impressed us. We highly recognize the R & D strength and commercial vision of the team and look forward to this round of financing helping the company accelerate the global clinical breakthrough of its core products."
Mr. Hu Xubo, Managing Partner of Qiming Venture Partners, said: "As an early investor accompanying Oricell since the Pre-A round, we have witnessed every step of the company's leap from technological exploration to pipeline implementation, clinical progress, and from local innovation to global layout. We look forward to Oricell achieving the next generation of cancer treatment with breakthrough cell therapy solutions and better clinical data, and bringing hopes of cure to global cancer patients."